Inhibitors of dipeptidyl-peptidase-4: obvious and probable (literature review)

• Published in: Medicinskij sovet no. 10; pp. 40 - 45
• Main Authors: Ortenberg, E. A., Suplotova, L. A.
• Format: Journal Article
• Language: English
• Published: Remedium Group LLC 18-06-2022
• Subjects: alzheimer’s disease; colorectal cancer; covid-19; diabetes mellitus; dpp-4 inhibitors
• ISSN: 2079-701X; 2658-5790
• DOI: 10.21518/2079-701X-2022-16-10-40-45

The purpose of the presented literature review was an attempt to sum up current estimates of the effect of the use of dipeptidyl peptidase-4 inhibitors (iDPP-4) in the algorithms of both traditional (diabetes mellitus) and a number of alternative nosologies, in particular, oncological and neurological pathology, as well as a new coronavirus infection (COVID-19). To do this, the most large-scale (as a rule) publications of 2018–2021 devoted to the problems under consideration were analyzed. The search was carried out by keywords in the Pubmed information base
(ncbi.nlm.nih.go
v). Factors contributing to the widespread use of IDP-4 in clinical practice are both pharmacologically clear mechanism of action and efficacy, as well as the possibility of oral use, a successful pharmacokinetic profile, low toxicity, in particular, a low risk of hypoglycemia. Newly obtained data on the mechanisms of mechanisms are discussed. Renoprotective action, the presence of cardioprotection is debated. The biochemical prerequisites for the possible effectiveness of iDPP-4 as blockers of the development of a hyperimmune reaction that causes, in particular, the severe course of the new coronavirus infection are discussed. At the same time, the results of studies of various designs are categorically compared, indicating both in favor of the use of iDPP-4 in patients with COVID-19, and not noticing its expediency. It is concluded that, given the large-scale biochemical role of DPP-4, it is important both to continue the active use of its inhibitors in diabetes mellitus, and to expand attempts to use them in a number of other nosologies, including COVID-19.